Remission of autoimmune diabetes by anti-TCR combination therapies with anti-IL-17A or/and anti-IL-6 in the IDDM rat model of type 1 diabetes.
Antibody combination therapy
IL-17
IL-6
LEW.1AR1-iddm rat
Pancreatic beta cells
Reversal of hyperglycaemia
Type 1 diabetes
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
28 02 2020
28 02 2020
Historique:
received:
20
09
2019
accepted:
27
01
2020
entrez:
29
2
2020
pubmed:
29
2
2020
medline:
23
9
2020
Statut:
epublish
Résumé
The cytokine IL-17 is a key player in autoimmune processes, while the cytokine IL-6 is responsible for the chronification of inflammation. However, their roles in type 1 diabetes development are still unknown. Therefore, therapies for 5 days with anti-IL-17A or anti-IL-6 in combination with a T cell-specific antibody, anti-TCR, or in a triple combination were initiated immediately after disease manifestation to reverse the diabetic metabolic state in the LEW.1AR1-iddm (IDDM) rat, a model of human type 1 diabetes. Monotherapies with anti-IL-6 or anti-IL-17 showed no sustained anti-diabetic effects. Only the combination therapy of anti-TCR with anti-IL-6 or anti-IL-17 at starting blood glucose concentrations up to 12 mmol/l restored normoglycaemia. The triple antibody combination therapy was effective even up to very high initial blood glucose concentrations (17 mmol/l). The β cell mass was raised to values of around 6 mg corresponding to those of normoglycaemic controls. In parallel, the apoptosis rate of β cells was reduced and the proliferation rate increased as well as the islet immune cell infiltrate was strongly reduced in double and abolished in triple combination therapies. The anti-TCR combination therapy with anti-IL-17 preferentially raised the β cell mass as a result of β cell proliferation while anti-IL-6 strongly reduced β cell apoptosis and the islet immune cell infiltrate with a modest increase of the β cell mass only. The triple combination therapy achieved both goals in a complimentary anti-autoimmune and anti-inflammatory action resulting in sustained normoglycaemia with normalized serum C-peptide concentrations.
Sections du résumé
BACKGROUND
The cytokine IL-17 is a key player in autoimmune processes, while the cytokine IL-6 is responsible for the chronification of inflammation. However, their roles in type 1 diabetes development are still unknown.
METHODS
Therefore, therapies for 5 days with anti-IL-17A or anti-IL-6 in combination with a T cell-specific antibody, anti-TCR, or in a triple combination were initiated immediately after disease manifestation to reverse the diabetic metabolic state in the LEW.1AR1-iddm (IDDM) rat, a model of human type 1 diabetes.
RESULTS
Monotherapies with anti-IL-6 or anti-IL-17 showed no sustained anti-diabetic effects. Only the combination therapy of anti-TCR with anti-IL-6 or anti-IL-17 at starting blood glucose concentrations up to 12 mmol/l restored normoglycaemia. The triple antibody combination therapy was effective even up to very high initial blood glucose concentrations (17 mmol/l). The β cell mass was raised to values of around 6 mg corresponding to those of normoglycaemic controls. In parallel, the apoptosis rate of β cells was reduced and the proliferation rate increased as well as the islet immune cell infiltrate was strongly reduced in double and abolished in triple combination therapies.
CONCLUSIONS
The anti-TCR combination therapy with anti-IL-17 preferentially raised the β cell mass as a result of β cell proliferation while anti-IL-6 strongly reduced β cell apoptosis and the islet immune cell infiltrate with a modest increase of the β cell mass only. The triple combination therapy achieved both goals in a complimentary anti-autoimmune and anti-inflammatory action resulting in sustained normoglycaemia with normalized serum C-peptide concentrations.
Identifiants
pubmed: 32106855
doi: 10.1186/s12916-020-1503-6
pii: 10.1186/s12916-020-1503-6
pmc: PMC7047363
doi:
Substances chimiques
IL17A protein, human
0
Interleukin-17
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : JO 395/2-2
Pays : International
Références
Arthritis Res Ther. 2011 Jul 30;13(4):R126
pubmed: 21801431
Immunol Lett. 2016 Jun;174:9-18
pubmed: 27058440
Nat Commun. 2014 Jun 09;5:3986
pubmed: 24909159
Dig Dis. 2017;35(1-2):5-12
pubmed: 28147353
Mediators Inflamm. 2005 Oct 24;2005(5):273-9
pubmed: 16258194
Actas Dermosifiliogr. 2017 May;108(4):305-314
pubmed: 27887675
Clin Exp Immunol. 2010 May;160(2):176-84
pubmed: 20629979
Arch Pharm Res. 2016 Nov;39(11):1537-1547
pubmed: 27576555
Diabetes Care. 2018 Nov;41(11):2396-2403
pubmed: 30254083
Rheum Dis Clin North Am. 2014 Nov;40(4):797-811
pubmed: 25437293
Mediators Inflamm. 2015;2015:290657
pubmed: 26792955
Ther Clin Risk Manag. 2016 Oct 21;12:1587-1592
pubmed: 27799780
Eur J Clin Invest. 2018 Nov;48(11):e13021
pubmed: 30155878
J Mol Med (Berl). 2014 Jul;92(7):743-55
pubmed: 24599515
Lancet. 2014 Jan 4;383(9911):69-82
pubmed: 23890997
Diabetologia. 2001 Sep;44(9):1189-96
pubmed: 11596676
Rev Colomb Psiquiatr. 2018 Jul - Sep;47(3):177-186
pubmed: 30017041
Dis Model Mech. 2016 Apr;9(4):427-40
pubmed: 26822477
Drug Des Devel Ther. 2017 May 24;11:1593-1603
pubmed: 28579757
Clin Immunol. 2013 Dec;149(3):279-85
pubmed: 23510726
Nat Rev Endocrinol. 2015 May;11(5):289-97
pubmed: 25688000
Nat Immunol. 2017 May 18;18(6):604-611
pubmed: 28518154
Diabetologia. 2014 Mar;57(3):512-21
pubmed: 24310561
BioDrugs. 2018 Dec;32(6):531-546
pubmed: 30488231
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Rheumatology (Oxford). 2016 Dec;55(suppl 2):ii43-ii55
pubmed: 27856660
Am J Clin Dermatol. 2016 Feb;17(1):33-47
pubmed: 26649440
Diabetes Metab Res Rev. 2017 Oct;33(7):
pubmed: 28692149
Diabetes. 2006 Dec;55(12):3238-45
pubmed: 17130466
J Exp Med. 2007 Jan 22;204(1):41-7
pubmed: 17227914
Immunol Lett. 2014 May-Jun;159(1-2):30-5
pubmed: 24576850
Biochim Biophys Acta Gen Subj. 2017 Aug;1861(8):1929-1942
pubmed: 28527893
Am J Physiol Renal Physiol. 2016 Sep 1;311(3):F555-61
pubmed: 27279492
Cytokine. 2016 Oct;86:92-99
pubmed: 27497159
Diabetologia. 2014 Mar;57(3):502-11
pubmed: 24352375
Drugs R D. 2017 Mar;17(1):29-51
pubmed: 27838901
Diabetes. 2015 Aug;64(8):2880-91
pubmed: 25784545
Curr Drug Targets. 2013 Nov;14(12):1508-21
pubmed: 24102406
Arch Pharm Res. 2015;38(5):575-84
pubmed: 25648633
Lancet. 2011 Aug 6;378(9790):459-60
pubmed: 21719098
Diabetologia. 2015 Dec;58(12):2800-9
pubmed: 26363782
Cytokine. 2011 Aug;55(2):195-201
pubmed: 21531147
J Leukoc Biol. 2016 Jun;99(6):1153-64
pubmed: 26729813
Diabetologia. 2010 Apr;53(4):614-23
pubmed: 20225393
Diabetes. 2018 Jul;67(7):1216-1225
pubmed: 29769238
Biochem Pharmacol. 2015 Sep 1;97(1):16-26
pubmed: 26080005
Immunity. 2010 Nov 24;33(5):791-803
pubmed: 21074460
Annu Rev Med. 2016;67:337-53
pubmed: 26565676
Arthritis Rheum. 2001 Sep;44(9):2176-84
pubmed: 11592383
Autoimmun Rev. 2014 Jun;13(6):668-77
pubmed: 24418308
Diabetes. 2011 Aug;60(8):2112-9
pubmed: 21659501
Diabetes. 2017 Feb;66(2):448-459
pubmed: 28108611
Mult Scler. 2013 Jun;19(7):885-90
pubmed: 23207971
Diabetes Care. 2018 Apr;41(4):653-661
pubmed: 29559451
J Allergy Clin Immunol. 2016 Apr;137(4):1079-1090
pubmed: 27059729